These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32070867)

  • 1. A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress.
    Hu X; Zhang ZY; Wu LW; Zeng LH; Chen H; Zhu HJ; Zhang JK; Shao J; Zhang C; Li YL; Lin NM
    Phytomedicine; 2020 Mar; 68():153189. PubMed ID: 32070867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
    Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
    Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
    Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
    Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
    Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
    [No Abstract]   [Full Text] [Related]  

  • 7. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer.
    Wu S; Zhao Q; Liu S; Kuang J; Zhang J; Onga A; Shen Y; Wang J; Sui H; Ni L; Ye Y; Tu X; Le HB; Zheng Y; Cui R; Zhu W
    Int J Oncol; 2024 Aug; 65(2):. PubMed ID: 38873997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gambogic Acid Shows Anti-Proliferative Effects on Non-Small Cell Lung Cancer (NSCLC) Cells by Activating Reactive Oxygen Species (ROS)-Induced Endoplasmic Reticulum (ER) Stress-Mediated Apoptosis.
    Zhu M; Jiang Y; Wu H; Shi W; Lu G; Cong D; Liu K; Song S; Ren J
    Med Sci Monit; 2019 May; 25():3983-3988. PubMed ID: 31138775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells.
    Tang ZH; Cao WX; Su MX; Chen X; Lu JJ
    Toxicol Appl Pharmacol; 2017 Apr; 321():18-26. PubMed ID: 28237877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer.
    Park J; Purushothaman B; Hong S; Choi M; Jegal KH; Park M; Song JM; Kang KW
    Life Sci; 2024 Jul; 348():122681. PubMed ID: 38697281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
    Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.
    Dai CH; Zhu LR; Wang Y; Tang XP; Du YJ; Chen YC; Li J
    J Cell Physiol; 2021 Jun; 236(6):4538-4554. PubMed ID: 33230821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
    Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
    J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.
    Zhang Q; Chen M; Cao L; Ren Y; Guo X; Wu X; Xu K
    Mol Carcinog; 2020 Jun; 59(6):590-603. PubMed ID: 32189414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
    Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
    Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
    Remon J; Planchard D
    Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.